Rauchenzauner Markus, Haberlandt Edda, Scholl-Bürgi Sabine, Ernst Barbara, Hoppichler Fritz, Karall Daniela, Ebenbichler Christoph F, Rostasy Kevin, Luef Gerhard
Department of Paediatrics IV, Division of Neuropediatrics, Medical University Innsbruck, Austria.
Epilepsia. 2008 Feb;49(2):353-7. doi: 10.1111/j.1528-1167.2007.01460.x. Epub 2007 Dec 6.
Chronic antiepileptic therapy with valproic acid (VPA) is associated with increased body weight and insulin resistance in adults and children. Attempts to determine the underlying pathophysiologic mechanisms have failed. Adipocytokines have recently been defined as a link between glucose and fat metabolism. We herein demonstrate that VPA-associated overweight is accompanied by lower adiponectin and higher leptin concentrations in children. The absence of any relationship with visfatin concentration does not suggest a role of this novel insulin-mimetic hormone in VPA-associated metabolic alterations. Therefore, adiponectin and leptin but not visfatin may be considered as potential regulators of glucose and fat metabolism during VPA-therapy.
丙戊酸(VPA)的长期抗癫痫治疗与成人及儿童体重增加和胰岛素抵抗相关。确定潜在病理生理机制的尝试均未成功。脂肪细胞因子最近被定义为葡萄糖和脂肪代谢之间的联系。我们在此证明,VPA相关的超重儿童伴有脂联素水平降低和瘦素浓度升高。与内脂素浓度无任何关系表明这种新型胰岛素模拟激素在VPA相关代谢改变中不起作用。因此,在VPA治疗期间,脂联素和瘦素而非内脂素可能被视为葡萄糖和脂肪代谢的潜在调节因子。